Literature DB >> 9471116

Functional magnetic resonance imaging brain mapping in psychiatry: methodological issues illustrated in a study of working memory in schizophrenia.

J H Callicott1, N F Ramsey, K Tallent, A Bertolino, M B Knable, R Coppola, T Goldberg, P van Gelderen, V S Mattay, J A Frank, C T Moonen, D R Weinberger.   

Abstract

Functional magnetic resonance imaging (fMRI) is a potential paradigm shift in psychiatric neuroimaging. The technique provides individual, rather than group-averaged, functional neuroimaging data, but subtle methodological confounds represent unique challenges for psychiatric research. As an exemplar of the unique potential and problems of fMRI, we present a study of 10 inpatients with schizophrenia and 10 controls performing a novel "n back" working memory (WM) task. We emphasize two key design steps: (1) the use of an internal activation standard (i.e., a physiological control region) to address activation validity, and (2) the assessment of signal stability to control for "activation" artifacts arising from unequal signal variance across groups. In the initial analysis, all but one of the patients failed to activate dorsolateral prefrontal cortex (DLPFC) during the working memory task. However, some patients (and one control) also tended to show sparse control region activation in spite of normal motor performance, a result that raises doubts about the validity of the initial analysis and concerns about unequal subject motion. Subjects were then matched for signal variance (voxel stability), producing a subset of six patients and six controls. In this comparison, the internal activation standard (i.e., motor activation) was similar in both groups, and five of six patients, including two whom were neuroleptic-naive, failed to activate DLPFC. In addition, a tendency for overactivation of parietal cortex was seen. These results illustrate some of the promise and pitfalls of fMRI. Although fMRI generates individual brain maps, a specialized survey of the data is necessary to avoid spurious or unreliable findings, related to artifacts such as motion, which are likely to be frequent in psychiatric patients.

Entities:  

Mesh:

Year:  1998        PMID: 9471116     DOI: 10.1016/S0893-133X(97)00096-1

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  69 in total

1.  Gene expression profiling reveals alterations of specific metabolic pathways in schizophrenia.

Authors:  Frank A Middleton; Karoly Mirnics; Joseph N Pierri; David A Lewis; Pat Levitt
Journal:  J Neurosci       Date:  2002-04-01       Impact factor: 6.167

2.  Prefrontal dopamine D1 receptors and working memory in schizophrenia.

Authors:  Anissa Abi-Dargham; Osama Mawlawi; Ilise Lombardo; Roberto Gil; Diana Martinez; Yiyun Huang; Dah-Ren Hwang; John Keilp; Lisa Kochan; Ronald Van Heertum; Jack M Gorman; Marc Laruelle
Journal:  J Neurosci       Date:  2002-05-01       Impact factor: 6.167

Review 3.  Insights and treatment options for psychiatric disorders guided by functional MRI.

Authors:  Tonmoy Sharma
Journal:  J Clin Invest       Date:  2003-07       Impact factor: 14.808

Review 4.  Functional magnetic resonance imaging: emerging clinical applications.

Authors:  Heather A Wishart; Andrew J Saykin; Thomas W McAllister
Journal:  Curr Psychiatry Rep       Date:  2002-10       Impact factor: 5.285

Review 5.  [Genetic and pharmacological effects on prefrontal cortical function in schizophrenia].

Authors:  Andreas Heinz; Dieter F Braus; Berenice Romero; Jürgen Gallinat; Imke Puls; Georg Juckel; Daniel R Weinberger
Journal:  Nervenarzt       Date:  2004-09       Impact factor: 1.214

6.  Evidence of IQ-modulated association between ZNF804A gene polymorphism and cognitive function in schizophrenia patients.

Authors:  Min Chen; Zhansheng Xu; Jinguo Zhai; Xin Bao; Qiumei Zhang; Huang Gu; Qiuge Shen; Lina Cheng; Xiongying Chen; Keqin Wang; Xiaoxiang Deng; Feng Ji; Chuanxin Liu; Jun Li; Qi Dong; Chuansheng Chen
Journal:  Neuropsychopharmacology       Date:  2012-02-29       Impact factor: 7.853

7.  Effects of mu opioid receptor antagonism on cognition in obese binge-eating individuals.

Authors:  Samuel R Chamberlain; Karin Mogg; Brendan P Bradley; Annelize Koch; Chris M Dodds; Wenli X Tao; Kay Maltby; Bhopinder Sarai; Antonella Napolitano; Duncan B Richards; Edward T Bullmore; Pradeep J Nathan
Journal:  Psychopharmacology (Berl)       Date:  2012-07-03       Impact factor: 4.530

Review 8.  Treatment of cognitive deficits associated with schizophrenia: potential role of catechol-O-methyltransferase inhibitors.

Authors:  José A Apud; Daniel R Weinberger
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

9.  Evidence for the contribution of NOS1 gene polymorphism (rs3782206) to prefrontal function in schizophrenia patients and healthy controls.

Authors:  Zhifang Zhang; Xiongying Chen; Ping Yu; Qiumei Zhang; Xiaochen Sun; Huang Gu; Hao Zhang; Jinguo Zhai; Min Chen; Boqi Du; Xiaoxiang Deng; Feng Ji; Chuanyue Wang; Yutao Xiang; Dawei Li; Hongjie Wu; Jun Li; Qi Dong; Chuansheng Chen
Journal:  Neuropsychopharmacology       Date:  2014-12-10       Impact factor: 7.853

10.  Enuresis as a premorbid developmental marker of schizophrenia.

Authors:  Thomas M Hyde; Amy Deep-Soboslay; Bianca Iglesias; Joseph H Callicott; James M Gold; Andreas Meyer-Lindenberg; Robyn A Honea; Llewellyn B Bigelow; Michael F Egan; Esther M Emsellem; Daniel R Weinberger
Journal:  Brain       Date:  2008-07-31       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.